1-4 of 4
Eric Raefsky, MD
Close
Sort by
Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy

Jesus Berdeja, MD, Michael Savona, MD, Luis Chu, MD, James Essell, MD, Patrick Murphy, MD, Todd Bauer, MD, Eric Raefsky, MD, Ralph V. Boccia, MD, Ian Flinn, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3193.
https://doi.org/10.1182/blood.V122.21.3193.3193
Published: 2013
Journal Articles

Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis

Michael Savona, MD, Zeqiang Ma, PhD, Laura DeBusk, PhD, Pranil Chandra, DO, Shile Liang, PhD, R. Seth Cooper, MD, Eric Raefsky, MD, Victor Gian, MD, Richard Hockett, MD, Jesus Berdeja, MD, P. Alan Lennon, PhD
Journal: Blood
Blood (2013) 122 (21): 5266.
https://doi.org/10.1182/blood.V122.21.5266.5266
Published: 2013
Journal Articles

Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

John D. Hainsworth, MD, Dana S. Thompson, MD, F. Anthony Greco, MD, Eric Raefsky, MD, Scott Lunin, MD, James Reeves, Jr., MD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2749.
https://doi.org/10.1182/blood.V120.21.2749.2749
Published: 2012
Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD
Journal: Blood
Blood (2010) 116 (21): 4015.
https://doi.org/10.1182/blood.V116.21.4015.4015
Published: 2010